Home » Stocks » Biogen

Biogen Inc. (BIIB)

Stock Price: $265.00 USD -1.80 (-0.67%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $267.00 +2.00 (0.76%) Oct 23, 7:54 PM

Stock Price Chart

Key Info

Market Cap 40.78B
Revenue (ttm) 14.26B
Net Income (ttm) 5.08B
Shares Out 153.88M
EPS (ttm) 30.38
PE Ratio 8.72
Forward PE 9.52
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 23, 2020
Last Price $265.00
Previous Close $266.80
Change ($) -1.80
Change (%) -0.67%
Day's Open 267.23
Day's Range 262.16 - 267.23
Day's Volume 1,016,153
52-Week Range 257.60 - 374.99

More Stats

Market Cap 40.78B
Enterprise Value 45.03B
Earnings Date (est) Feb 4, 2021
Ex-Dividend Date n/a
Shares Outstanding 153.88M
Float 153.62M
EPS (basic) 30.26
EPS (diluted) 30.38
FCF / Share 37.71
Dividend n/a
Dividend Yield n/a
Earnings Yield 11.46%
FCF Yield 14.51%
Payout Ratio n/a
Shares Short 2.83M
Short Ratio 2.25
Short % of Float 1.84%
Beta 0.52
PE Ratio 8.72
Forward PE 9.52
P/FCF Ratio 6.89
PS Ratio 2.86
PB Ratio 3.79
Revenue 14.26B
Operating Income 6.66B
Net Income 5.08B
Free Cash Flow 5.92B
Net Cash -4.25B
Net Cash / Share -27.65
Gross Margin 87.09%
Operating Margin 46.68%
Profit Margin 35.60%
FCF Margin 41.48%
ROA 15.95%
ROE 41.58%
ROIC 36.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (33)

Buy 10
Overweight 1
Hold 18
Underweight 2
Sell 2

Analyst Consensus: Overweight

Price Target

(10.51% upside)
Current: $265.00
Target: 292.85
*Average 12-month price target from 27 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth6.88%9.61%7.21%6.36%10.93%39.97%25.66%9.27%7.04%-
Gross Profit12,42311,63710,6449,9709,5238,5326,0754,9714,5824,316
Operating Income7,0435,8895,3465,1524,9223,9172,4911,8091,7251,249
Net Income5,8894,4312,5393,7033,5472,9351,8621,3801,2341,005
Shares Outstanding187205213218231236237238242252
Earnings Per Share31.4221.5811.9216.9315.3412.377.815.765.043.94
EPS Growth45.6%81.04%-29.59%10.37%24.01%58.39%35.59%14.29%27.92%-
Operating Cash Flow7,0796,1884,5514,5873,9192,9422,3451,8801,7281,625
Capital Expenditures-670-774-1,843-728-658-316-246-255-208-173
Free Cash Flow6,4095,4142,7083,8603,2612,6262,0991,6251,5201,452
Cash & Equivalents4,4763,5383,6894,8953,4291,8451,2231,7061,6911,208
Total Debt6,3685,9375,9386,5176,5265835961,1411,0641,204
Net Cash / Debt-1,892-2,399-2,249-1,622-3,0981,2626275656274.21
Book Value13,34313,04012,61312,1409,37310,8098,6206,9626,4255,397
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Biogen Inc.
Country United States
Employees 7,400
CEO Michel Vounatsos

Stock Information

Ticker Symbol BIIB
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Unique Identifier NASDAQ: BIIB
IPO Date September 16, 1991


Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it is involved in developing Opicinumab, BIIB061, and BIIB091 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB110, and BIIB100 to treat neuromuscular disorders; BIIB054 and BIIB094 for treating movement disorders; BIIB111 and BIIB112 for ophthalmology; Dapirolizumab pegol and BIIB059 to treat immunology and others; BIIB104 for neurocognitive disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB074 and BIIB095 for pain; and SB11 biosimilar, which are under various stages of development. The company offers products through its sales force and marketing groups. It has collaboration agreements with Genentech, Inc.; Ionis Pharmaceuticals, Inc.; Eisai Company; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Acorda Therapeutics, Inc.; AbbVie Inc.; Skyhawk Therapeutics, Inc.; Neurimmune SubOne AG; Scribe Therapeutics Inc.; and Sangamo Therapeutics Inc. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.